Global Cell Line Development Market 2022-2028

Global Cell Line Development Market 2022-2028

Cell line development is a major step for examining the efficiency of drug discovery, toxicity and in vitro testing. It reduces time, effort and cost, which minimises the chance of research drugs failing at the clinical trial stage. The global cell line development market size is projected to grow by USD 5 million from 2022 to 2028, registering a CAGR of 11.7 percent, according to a new report by Gen Consulting Company.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global cell line development market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the cell line development industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the product, source, type, application, and region. The global market for cell line development can be segmented by product: equipment, media and reagents. The media and reagents segment was the largest contributor to the global cell line development market in 2021. Cell line development market is further segmented by source: mammalian, non-mammalian. According to the research, the mammalian segment had the largest share in the global cell line development market. Based on type, the cell line development market is segmented into: continuous cell lines, hybridomas, primary cell lines, recombinant cell lines. On the basis of application, the cell line development market also can be divided into: bioproduction, drug discovery, tissue engineering, others. Cell line development market by region is categorized into: Asia Pacific, Europe, North America, Rest of the World (RoW).

By product:

• equipment
• media and reagents

By source:

• mammalian
• non-mammalian

By type:

• continuous cell lines
• hybridomas
• primary cell lines
• recombinant cell lines

By application:

• bioproduction
• drug discovery
• tissue engineering
• others

By region:

• Asia Pacific
• Europe
• North America
• Rest of the World (RoW)

The report explores the recent developments and profiles of key vendors in the Global Cell Line Development Market, including BioFactura, Inc., Corning Incorporated, Fujifilm Diosynth Biotechnologies, GE Healthcare, Horizon Discovery Group plc, LakePharma, Inc. (Curia Global, Inc.), Lonza Group AG, Merck KGaA, Rentschler Biopharma SE, Sartorius AG, Selexis SA (JSR Corporation), Thermo Fisher Scientific Inc., WuXi AppTec Co., Ltd., among others.

*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period

This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report

• To analyze and forecast the market size of the global cell line development market.
• To classify and forecast the global cell line development market based on product, source, type, application, region.
• To identify drivers and challenges for the global cell line development market.
• To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global cell line development market.
• To identify and analyze the profile of leading players operating in the global cell line development market.

Why Choose This Report

• Gain a reliable outlook of the global cell line development market forecasts from 2022 to 2028 across scenarios.
• Identify growth segments for investment.
• Stay ahead of competitors through company profiles and market data.
• The market estimate for ease of analysis across scenarios in Excel format.
• Strategy consulting and research support for three months.
• Print authentication provided for the single-user license.